AP2015008633A0 - Pyridone amides as modulators of sodium channels - Google Patents
Pyridone amides as modulators of sodium channelsInfo
- Publication number
- AP2015008633A0 AP2015008633A0 AP2015008633A AP2015008633A AP2015008633A0 AP 2015008633 A0 AP2015008633 A0 AP 2015008633A0 AP 2015008633 A AP2015008633 A AP 2015008633A AP 2015008633 A AP2015008633 A AP 2015008633A AP 2015008633 A0 AP2015008633 A0 AP 2015008633A0
- Authority
- AP
- ARIPO
- Prior art keywords
- modulators
- sodium channels
- pyridone amides
- pyridone
- amides
- Prior art date
Links
- -1 Pyridone amides Chemical class 0.000 title 1
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ink Jet (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759059P | 2013-01-31 | 2013-01-31 | |
| PCT/US2014/013652 WO2014120808A1 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008633A0 true AP2015008633A0 (en) | 2015-07-31 |
Family
ID=50073531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008633A AP2015008633A0 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US9051270B2 (ko) |
| EP (3) | EP3865475A1 (ko) |
| JP (4) | JP6389194B2 (ko) |
| KR (2) | KR102227592B1 (ko) |
| CN (2) | CN108164457B (ko) |
| AP (1) | AP2015008633A0 (ko) |
| AR (1) | AR094667A1 (ko) |
| AU (3) | AU2014212509B2 (ko) |
| BR (1) | BR112015018289A2 (ko) |
| CA (1) | CA2898866C (ko) |
| CL (1) | CL2015002147A1 (ko) |
| CY (1) | CY1119163T1 (ko) |
| DK (2) | DK2953931T3 (ko) |
| ES (2) | ES2857687T3 (ko) |
| GE (2) | GEP20207177B (ko) |
| HK (2) | HK1217693A1 (ko) |
| HR (2) | HRP20170787T1 (ko) |
| HU (2) | HUE053448T2 (ko) |
| IL (1) | IL240195B (ko) |
| LT (2) | LT2953931T (ko) |
| MX (2) | MX2021003687A (ko) |
| NZ (2) | NZ750187A (ko) |
| PE (2) | PE20151781A1 (ko) |
| PH (1) | PH12015501661A1 (ko) |
| PL (2) | PL3239134T3 (ko) |
| PT (2) | PT3239134T (ko) |
| RS (2) | RS61503B1 (ko) |
| RU (1) | RU2662223C2 (ko) |
| SG (2) | SG11201505953TA (ko) |
| SI (2) | SI3239134T1 (ko) |
| TW (2) | TWI714967B (ko) |
| UA (1) | UA120589C2 (ko) |
| UY (1) | UY35288A (ko) |
| WO (1) | WO2014120808A1 (ko) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| KR20140091022A (ko) | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| EA026393B1 (ru) | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-замещенные бензамиды и их применение в лечении боли |
| WO2014008458A2 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| WO2014120815A1 (en) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
| PT3239134T (pt) * | 2013-01-31 | 2021-01-28 | Vertex Pharma | Piridona amidas como moduladores dos canais de sódio |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| EA201691085A1 (ru) | 2013-11-27 | 2017-02-28 | Дженентек, Инк. | Замещенные бензамиды и способы их применения |
| SI3080134T1 (sl) | 2013-12-13 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| CA2986045A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| CN108137477A (zh) | 2015-08-27 | 2018-06-08 | 基因泰克公司 | 治疗化合物及其使用方法 |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| MA43304A (fr) | 2015-11-25 | 2018-10-03 | Genentech Inc | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
| MX2018009870A (es) | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Inhibidores de taf1 para la terapia del cancer. |
| US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| KR20190078587A (ko) | 2016-10-17 | 2019-07-04 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| CA3063901A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| MA49566A (fr) | 2017-07-11 | 2020-05-20 | Vertex Pharma | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
| TW202002971A (zh) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | 治療疼痛的方法 |
| WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| EA202191177A1 (ru) * | 2018-11-02 | 2021-07-28 | Мерк Шарп И Доум Корп. | 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8 |
| AU2020205139A1 (en) * | 2019-01-04 | 2021-08-19 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112996774B (zh) * | 2019-01-25 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| AU2020224245A1 (en) * | 2019-02-20 | 2021-08-05 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2021032074A1 (zh) * | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| MX2022003032A (es) * | 2019-09-12 | 2022-07-12 | Shanghai Jemincare Pharmaceuticals Co Ltd | Oxinitruro de piridina, metodo para su preparacion y uso de este. |
| AR120680A1 (es) | 2019-12-06 | 2022-03-09 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
| CN113045487A (zh) * | 2019-12-27 | 2021-06-29 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| CA3182633A1 (en) | 2020-06-17 | 2021-12-23 | Ashok Arasappan | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN114031518B (zh) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| JP7522943B2 (ja) | 2021-05-07 | 2024-07-25 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害薬としてのシクロアルキル ３－オキソピペラジンカルボキサミド類及びシクロヘテロアルキル ３－オキソピペラジンカルボキサミド類 |
| BR112023025264A2 (pt) | 2021-06-04 | 2024-02-20 | Vertex Pharma | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| WO2022256679A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AR126073A1 (es) | 2021-06-04 | 2023-09-06 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio |
| AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| CN116655497A (zh) * | 2022-02-25 | 2023-08-29 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
| US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AR129116A1 (es) | 2022-04-22 | 2024-07-17 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023207949A1 (zh) * | 2022-04-25 | 2023-11-02 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH598252A5 (ko) | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
| GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
| US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
| GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JP3285391B2 (ja) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | ２−フェノキシ安息香酸の製造法 |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO2001021652A1 (en) | 1999-09-24 | 2001-03-29 | The Johns Hopkins University School Of Medicine | Methods for identifying an agent that corrects defective protein folding |
| JP2003034671A (ja) * | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| EP1490064B1 (en) | 2002-02-14 | 2009-11-18 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
| EP2332912A1 (en) * | 2003-08-08 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain |
| KR100747401B1 (ko) * | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| CA2574600C (en) | 2004-07-23 | 2010-08-31 | Pfizer Inc. | Pyridine derivatives |
| AU2006254809B2 (en) | 2005-06-09 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| AU2006287480B2 (en) | 2005-09-09 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| WO2007047474A2 (en) | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| US8841483B2 (en) * | 2006-04-11 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP2183241B1 (en) | 2007-05-03 | 2012-12-19 | Pfizer Limited | 2-pyridine carboxamide derivatives as sodium channel modulators |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| EP2212290B1 (en) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| KR20100066583A (ko) * | 2007-10-11 | 2010-06-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압-개폐 나트륨 채널의 억제제로서 유용한 아미드 |
| JP5552430B2 (ja) * | 2007-10-31 | 2014-07-16 | メルク・シャープ・アンド・ドーム・コーポレーション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| CN102264722B (zh) * | 2008-12-23 | 2014-04-02 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮酰胺 |
| MX2011012712A (es) * | 2009-05-29 | 2012-01-30 | Raqualia Pharma Inc | Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio. |
| AR077033A1 (es) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| JP2013522305A (ja) | 2010-03-15 | 2013-06-13 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのスピロ−四環式環化合物 |
| EP2595989B1 (en) | 2010-05-06 | 2016-07-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| WO2012106499A1 (en) | 2011-02-02 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
| WO2012112462A1 (en) | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| KR101844623B1 (ko) | 2011-03-29 | 2018-04-02 | 사노피 | 안정성이 향상된 오타믹사반 제제 |
| JP5730398B2 (ja) | 2011-08-10 | 2015-06-10 | 三菱電機株式会社 | 誘導加熱調理器及びそのプログラム |
| CN102584774B (zh) | 2011-12-22 | 2014-08-06 | 合肥工业大学 | 一种呫吨酮类衍生物及其用途 |
| JP5823066B2 (ja) | 2012-03-06 | 2015-11-25 | ファイザー・インク | 増殖性疾患の治療のための大環状誘導体 |
| CN102659628B (zh) | 2012-04-26 | 2014-07-02 | 四川大学 | 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂 |
| WO2014120815A1 (en) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
| US9108903B2 (en) | 2013-01-31 | 2015-08-18 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| PT3239134T (pt) | 2013-01-31 | 2021-01-28 | Vertex Pharma | Piridona amidas como moduladores dos canais de sódio |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| SI3080134T1 (sl) | 2013-12-13 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov |
| MA49566A (fr) | 2017-07-11 | 2020-05-20 | Vertex Pharma | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
| TW202002971A (zh) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | 治療疼痛的方法 |
-
2014
- 2014-01-29 PT PT171524929T patent/PT3239134T/pt unknown
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 SI SI201431756T patent/SI3239134T1/sl unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/sl unknown
- 2014-01-29 UY UY0001035288A patent/UY35288A/es active IP Right Grant
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en active Application Filing
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/ru active
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/ja active Active
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/zh active Active
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 UA UAA201508443A patent/UA120589C2/uk unknown
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
- 2014-01-29 ES ES17152492T patent/ES2857687T3/es active Active
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
- 2014-01-29 PT PT147040539T patent/PT2953931T/pt unknown
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/es active IP Right Grant
- 2014-01-29 PL PL17152492T patent/PL3239134T3/pl unknown
- 2014-01-29 RS RS20210235A patent/RS61503B1/sr unknown
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/lt unknown
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/hu unknown
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 TW TW108105717A patent/TWI714967B/zh active
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/ko active IP Right Grant
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
- 2014-01-29 AR ARP140100281A patent/AR094667A1/es active IP Right Grant
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/es unknown
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 RS RS20170516A patent/RS56015B1/sr unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/es active Active
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/xx unknown
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/ko active IP Right Grant
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/es unknown
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/zh active Active
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/lt unknown
- 2014-01-29 TW TW103103691A patent/TWI655187B/zh active
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 PL PL14704053T patent/PL2953931T3/pl unknown
- 2014-01-29 MX MX2015009602A patent/MX2015009602A/es unknown
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/pt not_active Application Discontinuation
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/da active
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661A1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/es unknown
-
2016
- 2016-05-13 HK HK16105503.1A patent/HK1217693A1/zh unknown
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-26 HR HRP20170787TT patent/HRP20170787T1/hr unknown
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/el unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/ja active Active
- 2018-03-15 HK HK18103628.4A patent/HK1244269A1/zh unknown
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/ja not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/ja active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244269A1 (zh) | 作爲鈉通道調節劑的吡啶酮酰胺 | |
| HRP20181563T1 (hr) | Predlijekovi piridonskih amida korisni kao modulatori natrijevih kanala | |
| HK1217692A1 (zh) | 作為鈉通道調節劑的醯胺 | |
| HK1223604A1 (zh) | 用作鈉通道調節劑的磺醯胺類 | |
| HRP20182004T1 (hr) | Tetrahidropiridopirazini modulatori gpr6 | |
| HK1217691A1 (zh) | 作為鈉通道調節劑的喹啉及喹唑啉醯胺類 | |
| HK1223611A1 (zh) | 作為離子通道調節劑的稠合的呱啶醯胺類 |